Beta Bionics, Inc. Common Stock (BBNX) - Total Liabilities
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has total liabilities worth $33.17 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Beta Bionics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Beta Bionics, Inc. Common Stock's working capital to evaluate short-term liquidity relative to the company's equity base.
Beta Bionics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BELL AGROMACHINA ORD T (BSE)
NSE:BALUFORGE
|
India | Rs2.75 Billion |
|
Gemtek Technology Co Ltd
TW:4906
|
Taiwan | NT$5.74 Billion |
|
Groupe CRIT SA
PA:CEN
|
France | €875.15 Million |
|
GuangDong GenSho Logistics Co
SHG:603813
|
China | CN¥1.03 Billion |
|
Chatham Lodging Trust REIT
NYSE:CLDT
|
USA | $481.42 Million |
|
Movado Group Inc
NYSE:MOV
|
USA | $227.09 Million |
|
Floridienne
BR:FLOB
|
Belgium | €625.88 Million |
|
AnShan Heavy Duty Mining Machinery Co Ltd
SHE:002667
|
China | CN¥2.17 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Beta Bionics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Beta Bionics, Inc. Common Stock worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beta Bionics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Beta Bionics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $41.13 Million | -44.14% |
| 2024-12-31 | $73.63 Million | +43.16% |
| 2023-12-31 | $51.43 Million | +128.31% |
| 2022-12-31 | $22.53 Million | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more